HER-2 overexpression or ERBB-2 amplification is universal in many cancers, including breast cancer [12], colorectal cancer [13], lung cancer [14], ovarian cancer [15], gastric or gastroesophageal junction cancer [16], and so on. This evidence concerns the gene ERBB2 and lung carcinoma.